CHICAGO — A widely available anticholinergic significantly improved hot flash symptoms in men taking androgen deprivation therapy (ADT) for their prostate cancer, a researcher reported here.
In a double-blind randomized trial of 81 men, twice-daily oxybutynin significantly reduced hot flash severity — as measured by patient-reported hot flash scores — as well as the frequency of the common and bothersome ADT side effect, according to findings presented by Brad Stish, MD, of the Mayo Clinic in Rochester, Minnesota, at the American Society of Clinical Oncology (ASCO) meeting here.
At baseline, patients had hot flash scores of approximately 18 points. At 6 weeks, twice-daily oxybutynin at doses of 5 mg and 2.5 mg led to average reductions of 13.95 and 9.94 points, respectively, as compared with a 4.85-point reduction with placebo (P=0.0019 and P=0.0732). Of note, a prespecified P value
>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : MedPageToday – https://www.medpagetoday.com/meetingcoverage/asco/110457